How Does Abbott’s Revenue And Other Key Metrics Compare With That of Boston Scientific?
Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both engaged in the medical devices business. Abbott generates 3x the revenue when compared to Boston Scientific. For both the companies, revenue over the past few years has been impacted by acquisitions. Also, both the companies generate a significant portion of their revenues from the U.S. When it comes to profitability, Boston Scientific beats Abbott on gross profit. In this note we compare both the companies’ revenues and other key metrics. You can look at our interactive dashboard analysis ~ Abbott vs. Boston Scientific: How Have Revenues & Other Key Metrics Changed Over Recent Years? ~ for more details.
Abbott’s Revenues of $31 Billion Are Much Higher Than $10 Billion For Boston Scientific
- Abbott and Boston Scientific are both engaged primarily in the Medical Devices business.
- Abbott’s revenues grew from $20.2 billion in 2014 to $30.6 billion in 2018. Look at our analysis on Abbott’s revenues for more details.
- Boston Scientific’s revenues have grown from $7.4 billion in 2014 to $9.8 billion in 2018, led by its MedSurg business. Look at our interactive dashboard analysis for more details on Boston Scientific’s revenues.
Abbott’s Revenues Grew At A Higher Pace On Average When Compared To Boston Scientific
- Both Abbott and Boston Scientific saw growth in revenues in the recent years. And for both there was some impact of acquisitions in the sales growth.
- Boston Scientific’s revenue grew at a CAGR of 7.5% between 2014 and 2018, while the figure was 11.5% for Abbott over the same period.
- While Abbott’s growth in 2017 was aided by the St Jude acquisition, Boston Scientific’s growth in 2016 was bolstered by AMS portfolio and the Endochoice acquisition.
- Should You Pick Abbott Stock At $105 After An Upbeat Q1?
- After Nearly A 20% Rise In Six Months Will Abbott Stock See Higher Levels Post Q1?
- What’s Next For Abbott Stock After A 6% Rise This Year?
- Is Abbott Stock Undervalued At $95?
- Which Is A Better Pick – Abbott Stock Or Amgen?
- Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
U.S. Accounts For A Significant Portion of Total Sales For Both The Companies
- Abbott generated 35% of its total sales from the U.S. in 2018.
- For Boston Scientific, the figure stood at 56% in 2018.
Gross Profit Margin For Boston Scientific Is Better Than That For Abbott
- Abbott’s Gross Profit Margin grew from 54.5% in 2014 to 58.4% in 2018.
- Gross Profit Margin for Boston Scientific grew from 70.1% in 2014 to 71.4% in 2018.
Boston Scientific’s Adjusted Net Income Margin Has Been Trending Higher, And It Is Better Than That of Abbott
- Boston Scientific’s adjusted net income margin grew from 15.3% in 2014 to 21.0% in 2018.
- Abbott’s adjusted net income margin grew from 15.0% to 16.8% over the same period.
What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs
For CFOs and Finance Teams | Product, R&D, and Marketing Teams
Like our charts? Explore example interactive dashboards and create your own.